We have compared three bolus and infusion regimens of remifentanil on the cardiovascular response to laryngoscopy and orotracheal intubation in three groups of 20 ASA I-II female patients, in a randomized, double-blind study. Patients in group 1 received glycopyrrolate 200 µg i.v. followed by a bolus dose of remifentanil 1 µg kg -1 over 30 s and an infusion of remifentanil at a rate of 0.5 µg kg -1 min -1 . The other patients received remifentanil 0.5 µg kg -1 over 30 s and an infusion of 0.25 µg kg -1 min -1 with (group 2) or without (group 3) pretreatment with glycopyrrolate 200 µg. All patients then received a sleep dose of propofol, rocuronium 0.6 mg kg -1 and 1% isoflurane with 67% nitrous oxide in oxygen. Laryngoscopy and tracheal intubation were performed 3 min later. Heart rate and arterial pressure were recorded at 1-min intervals from before induction of anaesthesia until 5 min after intubation. Baseline heart rate was similar in all groups, but decreased in group 3 (no glycopyrrolate) after induction and remained significantly lower after intubation compared with the other groups (PϽ0.05). Heart rate and arterial pressure increased slightly after intubation in each group but there were no significant differences in mean arterial pressure between groups at any time. The incidence of bradycardia (one patient in group 2) and hypotension (two patients in groups 1 and 2 and three patients in group 3) was low. Laryngoscopy and tracheal intubation can cause tachycardia, Methods and results hypertension, arrhythmias, increased plasma catecholamine After obtaining approval from the Local Research Ethics concentrations and myocardial ischaemia in susceptible Committee and informed written consent, we studied 60 individuals. 1 These responses may be attenuated by i.v. ASA I-II female patients, aged 20-56 yr, presenting for opioids, vasodilators, calcium channel and β-blockers, or elective surgery. Patients were allocated to one of three deepening of anaesthesia. 1 Remifentanil is a new opioid groups in a randomized, double-blind manner. The groups with a rapid onset (1-2 min) and short duration of effect, were: glycopyrrolate 200 µg i.v. followed by a bolus dose which makes it ideal for attenuation of brief but noxious of remifentanil 1 µg kg -1 given over 30 s, and a subsequent stimuli. The dose of remifentanil recommended at induction infusion of remifentanil 0.5 µg kg -1 min -1 (group 1); and of anaesthesia is 1 µg kg -1 followed by an infusion of 0.25-remifentanil 0.5 µg kg -1 given over 30 s and an infusion of 1.0 µg kg -1 min -1 . 2 We have shown previously that this remifentanil 0.25 µg kg -1 min -1 preceded by glycopyrrolate dose attenuates the haemodynamic response to laryngoscopy 200 µg (group 2) or saline (group 3). All drugs were and tracheal intubation in healthy adults. 3 However, brady-prepared by an independent anaesthetist; the investigators cardia and hypotension occurred in five of 10 patients who were blinded to the identity of the drugs. did not receive pretreatment with glycopyrrolate and we Immediately after the bolus dose of remifentanil, anaespostulated that a lower dose of remifentanil might be thesia was induced with propofol 0.5 mg kg -1 followed by effective, without these side effects. We have therefore 10 mg every 10 s to loss of verbal contact, and rocuronium compared the haemodynamic response to laryngoscopy and tracheal intubation in patients receiving the recommended remifentanil regimen (with glycopyrrolate) or half this dose, †Presented in part to the Anaesthetic Research Society, University of Dundee, July 10, 1998 (Br J Anaesth 1998 81; 637P) both with and without glycopyrrolate pretreatment.
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© The Board of Management and Trustees of the British Journal of Anaesthesia 2000 Table 1 Mean (SD) cardiovascular variables before and after induction of anaesthesia and laryngoscopy and intubation in group 1 (1 µg bolus/0.5 µg kg -1 min -1 infusion, glycopyrrolate pretreatment), group 2 (0.5 µg bolus/0.25 µg kg -1 min -1 infusion, glycopyrrolate pretreatment) and group 3 (0.5 µg bolus/0.25 µg kg -1 min -1 infusion, no glycopyrrolate). *PϽ0.05 between groups
After induction
After laryngoscopy and intubation Baseline 1 min 2 min 3 min 1 min 2 min 3 min 4 min 5 min
Group 1 (nϭ20) SAP 125 (13) 111 (17) 100 (13) 94 (10) 105 (20) 100 (15) 96 (11) 93 (10) 93 (9) MAP 88 (11) 77 (18) 67 (13) 62 (11) 73 (16) 69 (14) 65 (10) 54 (9) 62 (8) DAP 72 (9) 62 (16) 56 (12) 50 (11) 61 (14) 57 (12) 53 (10) 52 (9) 51 (8) HR 84 (17) 86 (17) 82 (15) 81 (15) 86 (16) 86 (17) 84 (16) 82 (15) 80 15) Group 2 (nϭ20) SAP 127 (16) 110 (16) 98 (14) 92 (13) 109 (17) 102 (12) 94 (12) 92 (11) 91 (12) MAP 91 (14) 75 (13) 66 (12) 59 (11) 75 (13) 71 (10) 64 (10) 62 (10) 61 (10) DAP 76 (11) 62 (13) 53 (11) 47 (9) 63 (13) 58 (9) 52 (8) 48 (9) 50 (10) HR 85 (12) 86 (15) 85 (13) 81 (16) 90 (17) 86 (15) 83 (15) 81 (15) 78 (15) Group 3 (nϭ20) SAP 123 (13) 108 (13) 99 (9) 92 (9) 102 (12) 97 (11) 94 (9) 91 (9) 89 (8) MAP 88 (10) 75 (11) 64 (7) 60 (8) 71 (11) 65 (8) 61 (8) 58 (8) 57 (7) DAP 76 (10) 63 (13) 53 (8) 47 (7) 60 (12) 54 (9) 49 (8) 46 (7) 46 (7) HR 77 (13) 77 (12) 72 (12) 69 (11) 0.6 mg kg -1 . Patients' lungs were ventilated manually with (PϽ0.05). MAP increased by 11-16 mm Hg and mean HR increased by 6-11 beat min -1 after intubation, but within-1% isoflurane with 67% nitrous oxide in oxygen until intubation, and mechanically thereafter using a Manley or between-group differences in arterial pressure (SAP, MAP and DAP) were not statistically significant. Hypotension ventilator (tidal volume 10 ml kg -1 , end-tidal carbon dioxide partial pressure 4.0-4.5 kPa). Arterial pressure was meas-requiring escape medication occurred in two patients in groups 1 and 2 and in three patients in group 3. One patient ured non-invasively by an automatic oscillometer (Datex Cardiocap) and heart rate was recorded from the ECG in group 2 developed bradycardia requiring treatment. trace. Intubation was performed 3 min after induction of anaesthesia.
Comment
Heart rate (HR), systolic (SAP), mean (MAP) and diastolic (DAP) arterial pressures were recorded at 1-min We found no difference between a bolus dose of remifentanil 0.5 µg kg -1 followed by an infusion of 0.25 µg kg -1 min -1 intervals from before induction of anaesthesia to 5 min after intubation. Hypotension (SAP Ͻ80 mm Hg for Ͼ60 s) and twice these doses in attenuating the potential cardiovascular responses to laryngoscopy and orotracheal intubation. was treated with increments of ephedrine 3 mg i.v. or atropine 300 µg i.v. (if HR Ͻ50 beat min -1 ). Bradycardia Heart rate decreased after induction of anaesthesia in patients who did not receive glycopyrrolate, and remained (HR Ͻ45 beat min -1 for Ͼ60 s) was treated with atropine in increments of 300 µg.
significantly lower compared with the two other groups. However, the only episode of bradycardia that fulfilled our Power calculations based on our previous data 3 showed that 20 patients per group would be required to demonstrate criteria for escape medication occurred in a patient who received glycopyrrolate at induction (group 2). a difference in MAP of 15 mm Hg or HR of 15 beat min -1 (αϭ0.05, βϭ0.1), or a reduction in the incidence of A study in similar patients, using propofol, vecuronium 0.5 mg kg -1 and a bolus dose of remifentanil 1 µg kg -1 bradycardia or hypotension to 10% (αϭ0.05, βϭ0.2). Statistical analysis was performed using two-way and multi-followed by an infusion of 0.5 µg kg -1 min -1 , found that remifentanil was associated with bradycardia or hypotension variate analysis of variance for repeated measures (ANOVA, MANOVA with treatment group and time as the between-in five of 10 patients, compared with one of 10 in the group that also received glycopyrrolate 200 µg. 3 After a change and within-group factors) and paired and unpaired t tests with Bonferroni post-test analysis as appropriate using SPSS in hospital pharmacy policy, the neuromuscular blocking drug used in the present study was rocuronium 0.6 mg kg -1 , for Windows computer software (release 6.0, 1993) .
Mean ages were 34.4 (range 21-45) yr, 35.3 (24-56) yr which has a mild vagolytic effect and is associated with a lower incidence of bradycardia than vecuronium. 4 However, and 32.1 (20-48) yr in groups 1, 2 and 3, respectively. Mean weights were 67.6 (SD 11.6) kg, 69.2 (15.3) kg and mean MAP and HR immediately before laryngoscopy in the previous study were 59 mm Hg and 80 beat min -1 , 65.9 (15.7) kg, and propofol doses were 1.97 (0.46) mg kg -1 , 2.01 (0.42) mg kg -1 and 2.04 (0.54) mg kg -1 in the three which were very similar to the corresponding values reported here, despite the use of rocuronium. groups, respectively. Baseline SAP, MAP, DAP and HR were similar (Table 1) . Heart rate decreased in group 3
McAtamney and colleagues reported that after thiopental 5-7 mg kg -1 , a bolus dose of remifentanil 1 µg kg -1 was after induction of anaesthesia and remained lower after tracheal intubation compared with the other groups more effective in reducing the pressor response to intubation and resulted in a more rapid return to baseline values of the previous study 3 suggest that the recommended dose is excessive in healthy patients. heart rate and arterial pressure than 0.25 or 0.5 µg kg -1 . 5 In summary, we observed only slight changes in heart It is unclear if thiopental was titrated to effect. Heart rate and arterial pressure after laryngoscopy and tracheal rate increased in all treatment groups after induction of intubation when remifentanil 0.5 µg kg -1 i.v. given over anaesthesia and increased further after laryngoscopy and 30 s followed by an infusion of 0.25 µg kg -1 min -1 was intubation. Two of 20 patients in the remifentanil 1 µg kg -1 used as part of a balanced anaesthetic technique at induction group became hypotensive, although their heart rates were of anaesthesia in healthy adults. Heart rate was lower in not reported separately.
patients who did not receive glycopyrrolate, but only The same group examined the effect of remifentanil 0.5, one patient who had received glycopyrrolate developed 1.0 or 1.25 µg kg -1 on haemodynamic changes during rapid bradycardia requiring treatment. Hypotension requiring sequence induction of anaesthesia with thiopental escape medication occurred in two patients in groups 1 and 5-7 mg kg -1 and succinylcholine 1.0 mg kg -1 . 6 Remifentanil 2 and in three patients in group 3. 0.5 µg kg -1 was ineffective in controlling the pressor response but SAP was less than 90 mm Hg in seven of 20
